Controlled-release can deliver for generics firms, says Espicom

By Gareth Macdonald

- Last updated on GMT

Related tags Venlafaxine Pharmacology

Wyeth’s battles to protect the controlled-release (CR) version of its anti-depressant Effexor are a sign of things to come according to a new Espicom report identifying 30 CR drugs likely to face competition.

The study, “Emerging opportunities in controlled-release generic drugs,” claims the $15bn (€10.5bn) worth of CR medicines due to go off-patent in the medium term will be an irresistible opportunity for larger generics firms.

Espicom argues that although pharma firms are “[looking] at CR delivery earlier in the product life-cycle​” and, in some cases, launch CR versions ahead of patent expiry, such efforts are often the subject of challenges by generics firms keen to compete in the market.

The authors cites $3bn a year selling Effexor XR (venlafaxine) as an example of a CR product that has faced generic competition. They explain that although this version of the drug is protected in the US, a number of generics firms have filed Paragraph IV certifications under the Hatch-Waxman act.

At present several generics firms, including Sandoz, Wockhardt and Biovail, are the subject of Wyeth lawsuits for seeking Food and Drug Administration (FDA) approval to sell CR versions of venlafaxine in the US.

They authors also note that Wyeth has already settled litigation with Teva, Impax, Lupin and Anchen, all of which can introduce non-branded versions of controlled release venlafaxine over the next few years.

Lack of CR drug competition among generics firms

Espicom went on to suggest, however, that the opening up of the CR market will be a windfall for established generics firms with effective delivery technologies rather than smaller non-branded drugmakers that lack the funds to develop such platforms.

They authors argue that technical barriers to the development of CR drugs mean that firms able to produce them “will generally have fewer competitors in the marketplace and, therefore, will attract higher prices and greater revenue opportunities than the highly competitive instant-release formulations​.”

Related topics Ingredients Delivery technologies

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more